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Background. In clinical trials, equation 7 from the Modifi-
cation of Diet in Renal Disease (MDRD) Study is the most
accurate formula for the prediction of glomerular filtration rate
(GFR) from serum creatinine. An alternative approach has
been developed using evolving connectionist systems (ECOS),
which are novel computing structures that can be trained to
generate accurate output from a given set of input variables.
This study aims to compare the prediction errors associated
with each method, using data that reproduce routine clinical
practice as opposed to the artificial setting of clinical trials.
Methods. The methods were compared using 441 radioiso-
tope measurements of GFR in 178 chronic kidney disease pa-
tients from 12 centers in Australia and New Zealand. All clinical
and laboratory measurements were obtained from the patients’
center rather than central laboratories, as would be the case in
routine clinical practice. Both the MDRD formula and ECOS
used the same predictive variables, and both were optimized
to the study cohort by stepwise regression and training, respec-
tively.
Results. Mean measured GFR in the cohort was 22.6 mL/min/
1.73 m2. The bias and precision of the MDRD formula were
−3.5 mL/min/1.73 m2 and 34.5%, respectively, improving to
−1.2 mL/min/1.73 m2 and 31.1% after maximal optimization of
the formula to study data. The bias and precision of the ECOS
were 0.7 mL/min/1.73 m2 and 32.6%, respectively, improving to
−0.1 mL/min/1.73 m2 and 16.6% after maximal optimization of
the system to study data. The prediction of GFR using ECOS
was improved by accounting for the center from where clinical
and laboratory measurements originated within the connection-
ist model.
Conclusion. Algebraic formulas will be associated with
greater prediction error in routine clinical practice than in the
original trials, and machine intelligence is more likely to predict
GFR accurately in this setting.
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Accurate evaluation of renal function is fundamental
to sound nephrologic practice. Early detection of renal
disease allows for the institution of appropriate diagnos-
tic and therapeutic measures, and potentially maximizes
preservation of intact nephrons. As important, the eval-
uation of greater degrees of renal disease is useful to
provide additional information to determine the onset of
end-stage renal failure and facilitate the timely initiation
of dialysis.
Glomerular filtration rate (GFR) is recognized as the
best index of renal function [1]. GFR is most accurately
measured by the renal clearance of inulin during contin-
uous infusion. This procedure is technically demanding,
and alternative methods using radioisotope tracers pro-
duce results of comparable accuracy, and have now be-
come the gold standard for clinical research [2]. These are
still too cumbersome and costly for routine clinical use,
and most clinicians over the years have relied upon the
clearance of creatinine as a convenient and inexpensive
surrogate for GFR despite methodologic and systematic
inaccuracies.
More recently, formulas developed for the Modifica-
tion of Diet in Renal Disease (MDRD) Study have been
shown to predict GFR from serum creatinine with greater
accuracy than creatinine clearance [3]. In the original
study, over 90% of predicted values by equation 7 were
within 30% of measured GFR. These formulas, however,
have not been rigorously evaluated in a manner that
would reflect their use in routine clinical practice, namely
in a clinically diverse patient cohort using data measure-
ments originating from their respective centers. This is
especially applicable for patients with GFR <30 mL/
min/1.73 m2, where data have been relatively scarce and
studies conflicting as to whether any formulas are suffi-
ciently accurate to support good clinical decision-making
in the predialysis setting [4, 5].
Artificial neural networks are an alternative approach
to algebraic formulas for problem-solving in medical re-
search and routine clinical practice [6]. These are comput-
ing architectures that can be trained to generate accurate
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output from a given set of input variables. Artificial neu-
ral networks have several advantages in comparison to
traditional statistical models and the algebraic formulas
derived from them. Noisy data are well tolerated, and
no limiting assumptions regarding distribution are re-
quired. They outperform classic predictive tools in sit-
uations where input variables are interrelated, and are
increasingly used for nonlinear modeling dealing with
complex and chaotic problems [7].
Evolving connectionist systems (ECOS) are yet a fur-
ther advance in computing architecture. They allow a
departure from the usual paradigm of so-called “global
models,” in which statistical functions or mathematical
equations are developed and applied uniformly to the
entire “problem space.” A typical example of a global
model is the MDRD formula, which implicitly assumes
that relationships between predictive variables and GFR
are the same for every patient within a given cohort.
In contrast, ECOS involve a framework of multiple so-
called “local models,” in which different statistical models
or mathematical equations are developed and applied in
different clusters within the problem space. ECOS can
be provided with a self-mapping function by which new
data are allocated to whichever cluster or clusters are
closest in terms of the associated predictive variables.
From there, the local models unique to the allocated clus-
ter or clusters are applied to the new data in a weighted
fashion.
When training data are provided to such an ECOS (that
is, containing both predictive variables and the output),
then the ECOS will optimize both clustering and local
models within the clusters until error cannot be reduced
further, so-called “adaptive modeling” [8, 9].
There are two potential benefits to this ECOS frame-
work for medical applications. First, new training patient
data will result in incremental and autonomous machine
learning in a rapid continuous manner through on-line
changes to the connectionist structure and function, with-
out the necessity for down-time or complete de novo sys-
tem retraining on a new enhanced data set. Second, the
use of multiple local models has the potential for less pre-
dictive error than global models, by optimizing accuracy
within each patient subset of the total cohort rather than
relying on the application of a single model or equation
designed to provide the greatest accuracy to the great-
est number. ECOS appear particularly suitable for the
prediction of GFR in chronic kidney disease, where the
complex interrelation of patient factors and markers for
GFR make the estimation of renal function very diffi-
cult. This article has two aims: (1) to evaluate the ac-
curacy of algebraic formulas for the prediction of GFR
across a range of centers using center-specific data mea-
surements, and (2) to compare the performance of ECOS
using local modeling with these formulas on the same data
set.
METHODS
Study design
Reference GFR measurements by radioisotope tracer
clearance were compared with predicted GFR values
by alternative methods in a sample of patients from
Australia and New Zealand. The predictions were based
upon clinical and laboratory data from the day of GFR
measurement, using the algebraic formulas and the
ECOS as detailed below. The evolving nature of the latter
method was evaluated through the degree of improve-
ment in ECOS performance using progressively more
complex testing protocols in several discrete ECOS mod-
eling phases.
Data source
The EPO AUS-14 study was a prospective multicenter
randomized study conducted from 1998 to 2002 to de-
termine if maintenance of serum hemoglobin between
120 and 130 g/L prevented and/or delayed the devel-
opment of left ventricular hypertrophy in patients with
advanced kidney disease. The coordinating center did
the original selection of 12 centers in Australia and New
Zealand, and all incident patients fulfilling the criteria
for study were screened for participation. These criteria
were (1) age between 18 and 75 years, (2) GFR between
15 and 50 mL/min, and (3) demonstrated historic decline
in hemoglobin concentration to 110 to 130 g/L for males
and 100 to 120 g/L for females. Full details of the meth-
ods and results of the study have been reported elsewhere
[10]. EPO AUS-14 was approved by ethical review com-
mittees at respective institutions and informed consent
was obtained from all patients in accordance with the
guidelines proposed in the Declaration of Helsinki [11].
Patients
A sample of patients was drawn from EPO AUS-14 for
this study. In the original study, 296 patients were con-
sented and screened for randomization. We excluded pa-
tients from study if the date of GFR measurement by the
reference method did not coincide with the date of labo-
ratory testing, or if the protocol employed for this GFR
measurement differed from that stated below. A total of
178 patients from the original cohort were included in
this study. The demographic and clinical characteristics
of these patients are provided in Table 1.
Measurement of GFR
by chromium-51-ethylenediaminetetraacetic
acid (51Cr-EDTA) clearance
Reference GFR measurements were made for all pa-
tients at baseline and then yearly intervals for the du-
ration of the study. GFR was measured as the plasma
clearance of 51Cr-EDTA corrected for body surface area
1946 Marshall et al: ECOS for predicting renal function
Table 1. Baseline clinical characteristics of patients
Parameter Number (% of total) Mean Standard Deviation
Number of patients 178 — —
Number of gomerular filtration rate measurements 441 — —
Male 93 (52%) — —
Female 85 (48%) — —
White race 160 (89%) — —
Asian race 3 (2%) — —
Black race 15 (9%) — —
Angiotensin-converting enzyme inhibitor use 130 (74%) — —
3-hydroxy-3-methylglutaryl coenzymeA 69 (39%) — —
reductase inhibitor use
Loop diuretic use 76 (43.3%) — —
Diabetes mellitus 47 (26.4%) — —
Hypertension 165 (93.0%) — —
Congestive heart failure 4 (2.2%) — —
Ischemic heart disease 30 (16.9%) — —
Age 53.2 13.7
Weight kg 77.1 15.9
Height cm 167.8 9.6
Systolic blood pressure 141.2 21.5
Diastolic blood pressure 79.5 11.7
Serum creatinine mmol/L 0.35 0.21
Serum urea mmol/L 20.4 7.6
Serum albumin g/L 38.8 4.7
Hemoglobin 111.7 10.0
Left ventricular ejection fraction 65 7.4
Left ventricular mass g 162.8 57.7
Left ventricular mass index g/m2 87.0 26.7
(GFREDTA). Clearance was determined by either two or
three point sampling at variable intervals between 0.5 and
4.5 hours after tracer injection, with or without a correc-
tion for the monoexponential assumption. Samples were
processed in the nuclear medicine laboratories in each of
the respective centers. Median intratest and intertest co-
efficients of variation within and between these centres
were not studied and are therefore unavailable. A total
of 441 GFREDTA measurements were available for this
study, with an average of 2.5 measurements per patient
(range 1 to 4).
Prediction of GFR from serum creatinine
by algebraic formulas
GFR were predicted using the following algebraic for-
mulas, with clinical and laboratory input variables ob-
tained on the day of GFREDTA testing: (1) equation 7 as
described by the MDRD investigators in the original ar-
ticle [3] (analytes other than serum albumin in mg/dL,
serum albumin in g/dL, age in years):
GFRMDRD = 170 × (serum creatinine)−0.999
× (age)−0.167 × 0.762 (if sex is female)
× 1.180 (if race is black)
× (serum urea nitrogen)−0.170
× (serum albu min)+0.318
and (2) modified MDRD equation containing the same
variables, but different regression coefficients and mul-
tiplicative constants developed using multiple regression
analyses on the EPO AUS-14 data set (GFRmMDRD). Suc-
cessive GFRmMDRD equations were derived for each of
the ECOS modeling phases described below.
The rationale for modifying the original MDRD equa-
tion 7 is as follows: equation 7 was developed in a sam-
ple of the United States population to predict GFR as
measured by renal clearance of 125I-iothalamate. In this
study, patients were sampled from an Australian and New
Zealand population and GFR was measured by plasma
clearance of 51Cr-EDTA. The original MDRD equation
7 cannot therefore be expected to perform as well in this
data set as the original, due to patient related factors and
also the intertest variability between the two techniques
for radioisotope GFR measurement. A meaningful com-
parison between the MDRD equation and the ECOS de-
veloped in the new data set requires that the original
MDRD equation 7 be remodeled to optimize accuracy
under the new conditions. The modified MDRD equa-
tion and ECOS will therefore be products of the same
data set, and neither will be disadvantaged by being de-
veloped under one set of conditions and tested under
another.
Prediction of GFR by ECOS
GFR were predicted using the dynamic evolving
neuro-fuzzy inference system (DENFIS) [9], an ECOS
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that optimizes its generated output by learning from
training data using multiple local models. In this case, the
generated output was GFRDENFIS, and the training data
were comprised of the target output (GFREDTA) and the
clinical and laboratory variables to be associated with this
target output and therefore to be used for computational
modeling. DENFIS was engineered to report GFRDENFIS
as the average of ten internal modeling experiments for
both training and testing data. Background information
on DENFIS structure and function is available on the
website http://gfr-ecos.kedri.org.
Modeling phases for ECOS and algebraic formulas
Three phases of modeling were performed. The pur-
pose of the first phase of modeling was conventional vali-
dation of both the ECOS and modified MDRD formula.
Variables used for the training of DENFIS and modifi-
cation of the MDRD formula were the same six as were
used in the original MDRD equation 7. The EPO AUS-14
data set was randomly divided into training and testing
subdata sets, comprising 70% (309 renal function mea-
surements) and 30% (132 renal function measurements),
respectively, of the total. The GFRmMDRD equation was
derived from the training data set using stepwise multi-
ple regression analyses. The model for GFRDENFIS was
derived from the training data set within the ECOS as
previously described [9].
The purpose of the second phase of modeling was to
evaluate the effect of adaptive properties of DENFIS in
clinical practice. As previously, the EPO AUS-14 data set
was randomly divided into training and testing subdata
sets, but this time comprising 80% (353 renal function
measurements) and 20% (88 renal function measure-
ments), respectively, of the total. The GFRmMDRD equa-
tion was again derived from the training dataset using
stepwise multiple regression analyses and the usual six
variables. The modeling of DENFIS was performed in a
manner to closest reproduce its use in clinical practice.
The likeliest clinical scenario is that centers would be se-
quentially recruited to the ECOS over time, to join other
centers already using the trained system. The recruitment
of the new center would involve provision of some center-
specific training data to the ECOS, after which one could
expect accurate prediction of GFR for the new patients.
The “leave one out” method is the modeling protocol
that best reflects this clinical scenario. This protocol in-
volved dividing the EPO AUS-14 dataset into 12 subdata
sets according to the center of origin of the renal function
measurement. For a given center of interest, GFRDENFIS
was initially modeled by training on the other 11 cen-
ters. GFRDENFIS was then further modeled in the center
of interest by retraining on a random sample compris-
ing 80% of renal function measurements from that cen-
ter. This protocol was applied for each of the 12 centers.
The overall prediction error was then calculated as the
average error across the 12 centers from testing in the
remaining 20% of the measurements from each center.
This modeling protocol provides the most realistic reflec-
tion of ECOS performance with sequential recruitment
of centers to the system over time.
The purpose of the third and final phase of modeling
was to develop the most accurate ECOS and algebraic
formula possible, and compare the limits of optimization
for both frameworks. It should be noted that virtually
all algebraic formulas in common clinical use, including
the original MDRD equation 7 as published, have been
optimized by using the entire respective data sets for con-
current training and testing [3, 12–17]. The third phase of
modeling in this study was similarly undertaken using the
entire EPO AUS-14 data set for both training and testing
of both the ECOS and algebraic formula. The variables
used in the training of DENFIS and modification of the
MDRD formula were the same six as were used in the
original MDRD equation 7.
Modeling for both algebraic formulas and ECOS was
performed using Matlab version 6 software (Natick MA,
USA).
Statistical analysis
The accuracy of predicted GFR values (GFRMDRD,
GFRmMDRD, and GFRDENFIS) was determined by their
bias and precision in relation to reference GFR mea-
surements (GFREDTA). Absolute agreement or bias was
assessed by the mean difference between the predicted
GFR values and GFREDTA, which is the systematic differ-
ence between the methods. Relative agreement or preci-
sion was assessed by the fluctuation of these differences
around the mean. The standard deviation of these dif-
ferences can be quantified as the root mean square error
(RMSE), which can be expressed in mL/min/1.73 m2 or
as a percentage of GFR. The Bland-Altman procedure
was also used which defines range of agreement. This is
the mean difference ± 1.96 standard deviations, and rep-
resents how far apart predicted GFR values are likely to
be from reference GFR measurements for 95% of cases
[18, 19]. Analyses were made using Analyze-It version
1.62 software (Leeds, UK), and presented as scatter and
bias plots.
RESULTS
Results are presented as mean ± standard devia-
tion (range) unless otherwise specified. GFREDTA in the
cohort was 22.6 ± 10.7 (0.2 to 70) mL/min/1.73 m2.
GFRMDRD was 19.1 ± 9.3 (3.3 to 46.9) mL/min/1.73 m2.
GFRmMDRD was 21.0 ± 8.0 (4.2 to 40.8) mL/min/
1.73 m2 after the first phase of modeling, 22.3 ± 8.0 (3.0
to 45.4) mL/min/1.73 m2 after the second, and 21.4 ± 7.8
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Table 2. Agreement between predicted glomerular filtration rate (GFR) values and reference GFR measurements
95% limits of agreement
mL/min/1.73 m2Bias [95% CI] RMSE RMSE
Versus GFREDTA mL/min/1.73 m2 mL/min/1.73 m2 % of GFR Lower Upper
GFRMDRD −3.5 [−4.2, −2.9] 7.75 34.5% −17.2 10.1
Modeling phase 1
GFRmMDRD −1.6 [−2.3, −0.9] 7.59 33.6% −16.1 13.0
GFRDENFIS 0.7 [0.0. 1.3] 7.36 32.6% −13.7 15.0
Modeling phase 2
GFRmMDRD −0.3 [−0.9, 0.4] 7.08 31.3% −14.2 13.6
GFRDENFIS 0.1 [−0.6, 0.6] 6.75 29.9% −13.2 13.3
Modeling phase 3
GFRmMDRD −1.2 [−1.8, −0.6] 7.03 31.1% −14.8 12.4
GFRDENFIS −0.1 [−0.4, 0.3] 3.73 16.6% −7.4 7.2
RMSE is root mean square error, CI, confidence interval. Accuracy is reported for the testing subdata sets for the modeling phases 1 and 2 and for the entire data set
for GFRMDRD and modeling phase 3.
(6.4 to 41.2) mL/min/1.73 m2 after the third. The modi-
fied MDRD formula for Australians and New Zealanders
generated using the entire EPO AUS-14 data set from the
third phase of modeling was (analytes other than serum
albumin in mg/dL, serum albumin in g/dL, and age in
years):
GFRmMDRD = 120.4 × (serum creatinine)−0.825
× (age)−0.159 × 0.837 (if sex is female)
× 0.913 (if race is black)
× (serum urea nitrogen)−0.0114
× (serum albu min)+0.0651
GFRDENFIS was 23.2 ± 8.6 (5.0 to 47.6) mL/min/1.73 m2
after the first phase of modeling, 22.6 ± 8.7 (0.0 – 48.7)
mL/min/1.73 m2 after the second, and 22.5 ± 9.9 (5.0 to
64.6) mL/min/1.73 m2 after the third.
Statistical assessments of bias and precision of pre-
dicted GFR values are presented in Table 2 and
Figures 1 to 4. The prediction error of GFRDENFIS ver-
sus GFRmMDRD from the second phase of modeling for
each of the 12 centers is shown in Figure 5. It can be seen
that the ECOS outperformed the algebraic formula in
only certain centers. This finding can be further explored
considering Center 2 as a case study. Patients from Cen-
ter 2 had a marginally higher serum creatinine (0.40 ±
0.10 mmol/L) but a markedly lower GFREDTA (12.1 ±
6.7 mL/min/1.73 m2) when compared to the other centers.
The relationship between these two variables was there-
fore different in patients from Center 2, explaining the
improved prediction with local modelling via DENFIS
in comparison to global modeling via the GFRmMDRD.
There are several possible hypotheses to explain this
observation. Perhaps the patients from Center 2 were
biologically different with lower rates of creatinine pro-
duction. Indeed, patients from Center 2 did tend to be
female (60% of patients), older (mean age 60 years),
and none were black. Alternatively, laboratory assays for
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Fig. 1. Agreement of glomerular filtration rate according to the Modi-
fication of Diet in Renal Disease formula (GFRMDRD) with ethylenedi-
aminetetraacetic acid (GFREDTA) clearance (mL/min/1.73 m2). In the
scatter plot (A), the dotted line (········) represents the line of identity
between methods. In the bias plot (B), dotted lines represent the bias
between methods, broken lines (- · - ·) the range of agreement, and
the solid line the line of regression indicating bias according to level of
GFR.
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Fig. 2. Agreement of glomerular filtration rate according to the modified Modification of Diet in Renal Disease formula (GFRmMDRD) and dynamic
evolving neuro-fuzzy inference system (GFRDENFIS) with ethylenediaminetetraacetic acid (GFREDTA) clearance (mL/min/1.73 m2) from modeling
phase 1. In the scatter plots (A, C), the dotted lines (········) represent the line of identity between methods. In the bias plots (B, D), dotted lines
represent the bias between methods, broken lines (- · - ·) the range of agreement, and solid lines the line of regression indicating bias according to
level of GFR.
serum creatinine or measurements of GFREDTA may be
systematically lower in Center 2 than other centers. Ir-
respective of the reason, improved ECOS performance
in this second phase of modeling is due to additional
clustering and local model optimization, and allows for
improved prediction for patients within centers by ac-
counting for such center disposition.
Figure 6 shows the ECOS interface, with one of the
fuzzy rules generated by the trained DENFIS. Each rule
represents a local model associating predictive variables
with the generated output within a given cluster. All rules
together represent the equivalent of a global model that
can be applied for the prediction of GFR for any new
patient.
DISCUSSION
There seems little doubt that most clinicians will con-
tinue to rely on estimates of renal function from serum
creatinine to assist with clinical decision making, and an
array of algebraic formulas have been developed using
regression techniques to predict GFR from standard clin-
ical variables [20]. In the setting of clinical trials, the most
accurate of these formulas are those from the MDRD
Study [21–23].
The data from this study indicate that these formu-
las will be less accurate than expected in routine clinical
practice. However, modification of the original MDRD
equation 7 by multiple regression analyses within the
EPO AUS-14 data set did achieve some improvement
1950 Marshall et al: ECOS for predicting renal function
0
10
20
30
40
50
60
70
80
G
FR
 D
EN
FI
S
0 20 40 60 80
GFR EDTA
Identity line
A = B
A
−30
−20
−10
0
10
20
30
D
iff
e
re
n
ce
,
 
G
FR
 E
DT
A ,
 
G
FR
 D
EN
FI
S
Mean, GFR EDTA, GFR DENFIS
0 20 40 60 80
r = 0.33
B
Zero
bias
0
10
20
30
40
50
60
70
80
G
FR
 m
M
DR
D
0 20 40 60 80
GFR EDTA
Identity line
A = B
C
−30
−20
−10
0
10
20
30
D
iff
e
re
n
ce
,
 
G
FR
 E
DT
A ,
 
G
FR
 m
M
DR
D
Mean, GFR EDTA, GFR mMDRD
0 20 40 60 80
r = 0.42
D
Zero
bias
Fig. 3. Agreement of glomerular filtration rate according to the modified Modification of Diet in Renal Disease formula (GFRmMDRD) and dynamic
evolving neuro-fuzzy inference system (GFRDENFIS) with ethylenediaminetetraacetic acid (GFREDTA) clearance (mL/min/1.73 m2) from modeling
phase 2. In the scatter plots (A, C), the dotted lines (········) represent the line of identity between methods. In the bias plots (B, D), dotted lines
represent the bias between methods, broken lines (- · - ·) the range of agreement, and solid lines the line of regression indicating bias according to
level of GFR.
in absolute prediction error (bias) from −3.5 to −1.2 mL/
min/1.73 m2, and in relative prediction error (precision)
from 34.5% to 31.1%. This represents the best accuracy
that can be achieved in the study cohort by an algebraic
formula using the MDRD equation 7 template. It should
be noted that the modified MDRD formulas generated
for these analyses are not suitable for clinical use, as this
study constitutes insufficient validation in terms of (1) pa-
tient numbers and (2) the range of GFR measurements
over which the modified formulas were tested.
A fundamental methodologic feature of this study is
the prediction of GFR in multiple centers using center-
specific clinical and laboratory measurements. This study
design reproduces the use of these formulas in routine
clinical practice. To our knowledge, there are no similar
studies in the literature for comparison. Previous studies
have usually been undertaken in single centers, or in mul-
tiple centers but using central laboratories. The predic-
tion error from each of these individual studies cannot be
simply averaged for comparison with the data presented
here, although raw data could be pooled and reanalyzed.
There are several factors that led to the greater than
expected bias and imprecision of algebraic formulas in
this study. The minimum prediction error for GFR that
might be achievable by any method will be no less than the
measurement error of the reference method. The use of
central laboratories for the reference GFR measurement
reduces error since it is dependent on intra-test error only
(variation between the reported clearances of two forms
of the same marker administered to the same patient si-
multaneously). In this study and also in routine clinical
practice, the variety of reference methods that might be
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Fig. 4. Agreement of glomerular filtration rate according to the modified Modification of Diet in Renal Disease formula (GFRmMDRD) and dynamic
evolving neuro-fuzzy inference system (GFRDENFIS) with ethylenediaminetetraacetic acid (GFREDTA) clearance (mL/min/1.73 m2) from modeling
phase 3. In the scatter plots (A, C), the dotted lines (········) represent the line of identity between methods. In the bias plots (B, D), dotted lines
represent the bias between methods, broken lines (- · - ·) the range of agreement, and solid lines the line of regression indicating bias according to
level of GFR.
used in different laboratories leads to additional intertest
error (variation between the reported clearances of dif-
ferent marker standards administered to the same pa-
tient simultaneously). There are few published data that
definitively quantify these errors for GFR measurement,
although the most widely quoted estimates are ∼5% to
10% [2, 24, 25].
Another factor to consider is that the MDRD formu-
las were developed and validated within a study cohort
where only 3% had diabetes mellitus, and validated fur-
ther in the African American Study of Hypertension and
Kidney Disease study cohort where 100% were African
Americans and 0% had diabetes mellitus [26]. Similarly
unrepresentative patient samples have been used for the
development and validation of other popular formulas,
such as that by Cockcroft and Gault [14]. It is possible
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Fig. 5. Prediction error for glomerular filtration rate according to the
dynamic evolving neuro-fuzzy inference system (GFRDENFIS) () and
the modified Modification of Diet in Renal Disease (GFRmMDRD) ()
in each of the 12 centers from modeling phase 2.
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Fig. 6. Illustration of one of the dynamic evolving neuro-fuzzy inference system (DENFIS) computer interfaces. The problem space is visualized,
as is the progressive partitioning of the space for the ongoing creation of fuzzy rules. At each moment, GFRDENFIS is calculated through a fuzzy
inference system based on the most activated fuzzy rules that are dynamically selected from the existing fuzzy rule set. New fuzzy rules are created
and updated during the operation of the system. As an example, rule 13 is illustrated in the interface. Note that input variables are normalized
between zero and one. The entire complement of rules for the modeling of GFRDENFIS (modeling phase 3) are provided in the Web site http://gfr-
ecos.kedri.org.
and even likely that different ethnic populations such as
Asians, Hispanics, and Polynesians and also patients with
different comorbid medical burden will have different
biologic and therefore algebraic relationships between
GFR and its predictive variables such as serum creatinine.
Finally, analytical differences between laboratories in
measurement of analytes such as serum creatinine con-
tribute to the prediction error of these algebraic formulas.
Interlaboratory error has been evaluated in a number of
studies and may be as high as 15%, as a result of calibra-
tion differences to a great extent. It should be noted that
this error has progressively less impact with decreasing
GFR, and may be clinically insignificant in the predialysis
setting [27, 28]. Minimization of this error in the routine
clinical practice is possible through improved calibration
in laboratories to a single external standard, although
there will still be some error attributable to laboratory
methodology until it becomes more precise.
Given the difficulties in predicting GFR from serum
creatinine, should the clinician abandon such methods
and rely exclusively on the measurement of tracer clear-
ance? Radioisotope methods are accurate, and are known
to have a high degree of reproducibility across different
centers as long as computing algorithms are similar [29–
32]. These methods have been recommended as routine
by some authors [33], although their expense and logistics
limit utilization in most centers. The most accurate and
clinically accessible methods for measurement of GFR by
tracer clearance are first measured creatinine clearance
with cimetidine blockade [1], and second averaged mea-
sured urea and creatinine clearance [3]. The main disad-
vantage of these methods is the requirement for accurate
24-hour urine collection, and the potential for collection
error which can result in spurious day to day variation in
GFR of up to 70% [1].
In this article, we present a genuine alternative to all
these methods in a convenient and inexpensive form of
machine intelligence. ECOS has been shown to predict
GFR with greater accuracy than what is regarded as the
best of the available algebraic equations, even when the
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latter was also optimized using conventional statistical
modeling within the EPO AUS-14 data set. Moreover,
the second phase of modeling in our study illustrates the
potential beneficial of adaptive modeling with sequential
recruitment of centers to the system. In our study, such
improvement, however, was not achieved through the de-
velopment of discrete models for each center. Within
each center, up to 21 models were used to calculate
GFRDENFIS, with renal function measurements often al-
located to areas of the problem space partitioned to sev-
eral overlapping clusters. It is the weighted application of
these local models within the ECOS framework that pro-
vides the clinical benefit over and above global models
such as algebraic formulas.
The second phase of modeling also demonstrated an
important limitation of ECOS in clinical practice. In the
case study of Center 2, the ECOS was unable to distin-
guish whether the discrepancy between GFRmMDRD and
the corresponding GFREDTA arose from patient-related
factors or measurement error in laboratory parameters or
radioisotope tracer clearance. ECOS is still a tool based
on association rather than causality. However, unlike con-
ventional artificial neural networks it is still possible to
examine relationships among input and output variables
within the ECOS. The local models are in the form of
fuzzy rules that can be extracted and studied. Such rules
may allow for generation of hypotheses for further lab-
oratory or clinical testing, and also have the potential to
directly add to our understanding of underlying biologic
processes.
A feature of all of our modified MDRD formulas is
the factor of less than unity that is used to account for
black race, as opposed to 1.18 in the original MDRD
equation 7. In this study, the ethnic mix of “black” pa-
tients in Australia and New Zealand included Maori,
Polynesian, and Aboriginal patients, who are quite dis-
tinct from African Americans. It should not be assumed
that creatinine generation is higher in these ethnic groups
as is the case in African Americans. In our study co-
hort, the mean GFR was 18.73 mL/min and the mean
serum creatinine 0.42 mmol/L for patients classified as
black. The corresponding parameters were 22.9 mL/min
and 0.34 mmol/L for patients classified as white. If one
equates GFR with creatinine clearance and assumes a
steady state, the mean 24-hour creatinine generation is
11.3 mmol for both blacks and whites. The only other
available published data support this finding. The re-
lationship between calculated creatinine clearance and
urine creatinine was not different in Maoris, Polynesians,
and Europeans (P.A. Metcalf, personal communication,
July 26, 2004) [34]. This issue highlights again the poten-
tial in applying a formula such as the original MDRD
equation 7 in a population that is different from that in
which it has been developed.
The engineering of machine intelligence into tools of
medical practice is not difficult. Many medical devices
already have such systems embedded in them such as
arrhythmia detectors. Alternatively, the systems can be
placed on a central server as an internet or intranet-
based utility. If such computing resources were not avail-
able, these systems are amenable to rule extraction as
described. Such rules may be imported in a nonevolving
form into a hand-held device, although they would need
updating whenever advances in predictive modeling were
made.
This study has two limitations. The first of these is that
multiple GFR measurements were included for each pa-
tient. This methodology has occasionally been a feature
of previous studies of this nature [17], although is un-
desirable as formulas derived from regression analyses
will be biased toward patients with more frequent mea-
surements. We have compared demographic, clinical, and
laboratory characteristics of the patients in this study with
one or two GFR measurements, versus those with three
or four measurements. There were no demonstrable dif-
ferences in any of these parameters (data not shown),
indicating that the average frequency of 2.4 GFR mea-
surements per patient was unlikely to have confounded
our results. Ultimately, any limitation of the data set was
the same for both the algebraic formulas and the ECOS,
and the comparison of the two methods at the core of
this study still valid. The other limitation of this study
is its sample size: the MDRD study used 1070 and 558
GFR measurements for training and validation, respec-
tively, compared with 309 and 132 corresponding GFR
measurements in this study. This will inevitably limit the
power of the analyses presented in this study, although
we believe that study of a larger cohort would not have
produced different results.
CONCLUSION
This study strongly suggests that published algebraic
formulas for the prediction of GFR will be less accurate
than expected in routine clinical practice and confirms
that their performance can be improved somewhat by
additional regression analyses prior to clinical use in di-
verse populations. This study demonstrates machine in-
telligence to be workable with greater accuracy than such
algebraic formulas. Furthermore, there is potential to en-
hance modeling further within the ECOS framework by
the sequential inclusion of further clinical variables with
training data in the final model in the future. A Web-
based implementation of GFRDENFIS has been developed
by this group for further prospective multicenter study,
and it is hoped that the computational models so devel-
oped may in turn shed light upon biologic processes that
influence renal function and mitigate renal disease.
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